Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
usx:ocea Blog PostOcean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
usx:ocea Blog PostOcean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
usx:ocea Blog PostOcean Biomedical’s share price target averages $18.21 amid continued progress in research programs
usx:ocea Blog PostOcean Biomedical provides update on programs in malaria, fibrosis, and multiple cancers
usx:ocea Blog PostFundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
usx:ocea Blog PostOcean Biomedical announces loan commitment of up to $10 million from largest stockholder
usx:ocea Blog PostOcean Biomedical’s JV partner Virion presents positive oncology data at SITC 2023
usx:ocea Blog PostOcean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
usx:ocea Blog PostOcean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
usx:ocea Blog PostAIRO Group Holdings all set to go public through SPAC merger
usx:avav usx:joby usx:evex usx:ocea usx:krnlu Blog PostOcean Biomedical provides positive research data on anti-tumor pathway; stock climbs
usx:ocea Blog PostFundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
usx:pfe usx:ocea Blog Post